Hikari Power Ltd decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 47.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after selling 8,920 shares during the period. Hikari Power Ltd’s holdings in IDEXX Laboratories were worth $1,127,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of the company. Schroder Investment Management Group bought a new position in IDEXX Laboratories during the second quarter worth $503,000. Airain ltd bought a new position in IDEXX Laboratories during the second quarter worth $7,179,000. Welch & Forbes LLC increased its position in IDEXX Laboratories by 0.6% in the second quarter. Welch & Forbes LLC now owns 198,190 shares of the company’s stock worth $18,404,000 after buying an additional 1,169 shares in the last quarter. West Coast Financial LLC increased its position in IDEXX Laboratories by 1.1% in the second quarter. West Coast Financial LLC now owns 85,907 shares of the company’s stock worth $7,977,000 after buying an additional 973 shares in the last quarter. Finally, Columbus Circle Investors increased its position in IDEXX Laboratories by 7.0% in the second quarter. Columbus Circle Investors now owns 816,808 shares of the company’s stock worth $75,849,000 after buying an additional 53,560 shares in the last quarter. 90.75% of the stock is currently owned by institutional investors.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up 2.00% during midday trading on Wednesday, hitting $120.88. 108,675 shares of the stock traded hands. IDEXX Laboratories, Inc. has a 1-year low of $63.48 and a 1-year high of $121.81. The company has a 50-day moving average price of $118.92 and a 200-day moving average price of $111.32. The firm has a market cap of $10.84 billion, a P/E ratio of 51.48 and a beta of 0.51.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. The business had revenue of $448.30 million for the quarter, compared to the consensus estimate of $448.60 million. IDEXX Laboratories had a net margin of 12.36% and a negative return on equity of 788.91%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.48 earnings per share. Analysts predict that IDEXX Laboratories, Inc. will post $2.38 EPS for the current year.
A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, January 16th. Canaccord Genuity set a $125.00 price target on shares of IDEXX Laboratories and gave the stock a “buy” rating in a research note on Monday. Finally, Bank of America Corporation reaffirmed a “neutral” rating on shares of IDEXX Laboratories in a research note on Thursday, September 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $105.20.
In related news, Director William T. End sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $109.87, for a total transaction of $549,350.00. Following the completion of the sale, the director now directly owns 48,654 shares in the company, valued at $5,345,614.98. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Thomas Craig sold 8,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $120.06, for a total transaction of $1,020,510.00. Following the sale, the director now owns 32,783 shares of the company’s stock, valued at $3,935,926.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,112 shares of company stock worth $10,745,322. 2.79% of the stock is currently owned by insiders.
IDEXX Laboratories Company Profile
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).